Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | DDX3X | O00571 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9168407 | 0.94 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30021444 | 0.94 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL629093 | 0.90 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL8392853 | 0.89 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13363465 | 0.89 | HDAC1 (0.91) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10969527 | 0.89 | KDM4E (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9202717 | 0.87 | SOAT2 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9202711 | 0.87 | SOAT2 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15650429 | 0.86 | HDAC1 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9206018 | 0.85 | SOAT2 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0111844-B1 | PROCESS FOR THE PREPARATION OF 3-ACYLAMINOANILINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-11-27 | — | — | EP | disclosed |
| US-4552699-A | Process for the preparation of 3-acylaminoanilines | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-11-12 | — | — | US | disclosed |
| EP-0111844-A1 | Process for the preparation of 3-acylaminoanilines | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-27 | — | — | EP | disclosed |
| US-4039316-A | 3-Methoxy crotonanilides as herbicides | ROUSSEL UCLAF (FR) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | HDAC3 2772/4885HDAC4 2532/4885HDAC1 2964/4885 |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | HDAC3 4409/4885HDAC4 4344/4885HDAC1 4612/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | HDAC3 4038/4885HDAC4 4451/4885HDAC1 4523/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HDAC3 4549/4885HDAC4 4422/4885HDAC1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.